TY - JOUR
T1 - Threshold sodium excretory and renal blood flow effects of angiotensin converting enzyme inhibition
AU - Zhang, X.
AU - Dunham, E. W.
AU - Zimmerman, B. G.
PY - 1995
Y1 - 1995
N2 - Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6% and 18%, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37%). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44% to 78%, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.
AB - Objective: To probe the potential influence of a high renal tubular level of angiotensin II on sodium reabsorption using angiotensin converting enzyme inhibitors and a non-peptide angiotensin antagonist. Methods: Systemic arterial blood pressure, renal blood flow (RBF) and electrolyte and urinary excretion were measured in anesthetized uninephrectomized Wistar rats. Captopril (n = 12), ramiprilat (n = 10) or EXP 3174 (n = 9) was infused into the renal artery in graded doses to examine whether the threshold dose that increased RBF was lower than that which increased sodium excretion rate (Na+ excretion rate). Results: Whereas ramiprilat (0.5-4 μg/kg/min intra-arterially) and EXP3174 (0.5-4 μg/kg/min intra-arterially) decreased blood pressure in all but the lowest dose of 0.5 μg/kg/min, captopril (1-8 μg/kg/min intra-arterially) did not change blood pressure except for a slight effect with the two higher doses. These three agents increased RBF to about the same degree, between 6% and 18%, which was relatively large compared with the maximal vasodilator response achievable in the kidney with acetylcholine (30-37%). Captopril given intra-arterially had a more consistent effect on Na+ excretion rate than either ramiprilat or EXP3174. An increase in Na+ excretion rate occurred with captopril ranging from 44% to 78%, whereas no significant change was obtained with the other drugs. The dose of captopril that increased RBF was the same as that which increased Na+ excretion rate. In those experiments in which ramiprilat resulted in an increase in Na+ excretion rate (five of 10 experiments), the effective dose was the same as that which increased RBF. Conclusion: When administered by the intra-arterial route, captopril was more effective in increasing Na+ excretion rate than either ramiprilat or EXP 3174. Although the threshold dose of captopril and ramiprilat required to increase Na+ excretion rate and RBF was similar, suggesting blockade of a common angiotensin II pool, there was not a good correlation between these two effects.
KW - Angiotensin II
KW - Angiotensin antagonist
KW - Kidney
KW - Renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=0029616340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029616340&partnerID=8YFLogxK
U2 - 10.1097/00004872-199512000-00007
DO - 10.1097/00004872-199512000-00007
M3 - Article
C2 - 8866903
AN - SCOPUS:0029616340
SN - 0263-6352
VL - 13
SP - 1413
EP - 1419
JO - Journal of hypertension
JF - Journal of hypertension
IS - 12 I
ER -